![](/fileadmin/_processed_/e/1/csm_0420-209_Infographic_Hero_4e190a072f.png)
Peeking into the CGT Pipeline
Intel shows a rise in cell and gene therapy development in the US, with China not far behind
![](/fileadmin/_processed_/4/c/csm_0420-209_Infographic_In_Article_519937b289.png)
![](/fileadmin/_processed_/0/e/csm_0420-209_Infographic_In_Article2_0a33dc774f.png)
![](/fileadmin/_processed_/3/d/csm_0420-209_Infographic_In_Article3_24eb9fa856.png)
![](/fileadmin/_processed_/c/6/csm_0420-209_Infographic_In_Article4_d57f56bcb4.png)
Sources
PhRMA, “Medicines in Development 2020 Update: Cell and Gene Therapy” (2020).
Beacon Targeted Therapies, “Our Highlights from CAR-TCR Europe 2020) (2020).
![](/fileadmin/_processed_/1/f/csm_James-716_6340afb872.png)
Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.
From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.